Daphnetin treatment inhibits the proliferation and inflammatory response of human HaCaT keratinocytes and ameliorates imiquimod (IMQ)-induced psoriasis-like skin injury in mice and attenuates the IMQ-induced upregulation of inflammatory cytokines, including IL-6, IL-23A, and IL-17A (91). This evidence concerns the gene IL6 and psoriasis.